Insider Selling: SI-BONE, Inc. (NASDAQ:SIBN) Insider Sells 3,311 Shares of Stock

SI-BONE, Inc. (NASDAQ:SIBN) insider Anthony J. Recupero sold 3,311 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $14.15, for a total value of $46,850.65. Following the completion of the transaction, the insider now directly owns 284,555 shares of the company’s stock, valued at $4,026,453.25. This represents a 1.15 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

SI-BONE Trading Down 1.0 %

SI-BONE stock opened at $13.47 on Friday. SI-BONE, Inc. has a 12 month low of $11.70 and a 12 month high of $19.16. The company has a market capitalization of $571.84 million, a price-to-earnings ratio of -14.64 and a beta of 1.02. The business’s fifty day simple moving average is $16.14 and its two-hundred day simple moving average is $14.72. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22.

SI-BONE (NASDAQ:SIBN) last announced its quarterly earnings results on Monday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. The company had revenue of $49.00 million for the quarter, compared to analysts’ expectations of $48.87 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. As a group, equities analysts predict that SI-BONE, Inc. will post -0.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SI-BONE

Institutional investors have recently made changes to their positions in the company. FMR LLC raised its holdings in SI-BONE by 103.6% in the 3rd quarter. FMR LLC now owns 2,354 shares of the company’s stock worth $33,000 after acquiring an additional 1,198 shares during the last quarter. Virtus Fund Advisers LLC purchased a new position in shares of SI-BONE in the fourth quarter worth $40,000. Mainstream Capital Management LLC purchased a new position in shares of SI-BONE in the fourth quarter worth $53,000. R Squared Ltd bought a new position in shares of SI-BONE during the fourth quarter valued at $73,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of SI-BONE during the fourth quarter valued at $97,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on SIBN. Truist Financial reaffirmed a “buy” rating and issued a $22.00 price target (up from $18.00) on shares of SI-BONE in a research note on Tuesday, February 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 target price on shares of SI-BONE in a research report on Tuesday, February 25th. Finally, Needham & Company LLC increased their price target on shares of SI-BONE from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $24.40.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.